DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics ...

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned diagnostics provider posted adjusted earnings per share (EPS ...

Despite a change in ownership, the diverse mix of tenants is expected to remain at this popular Beach Boulevard marketplace.

A public health advocacy group is urging the B.C. government to end its contract with the American company that owns LifeLabs ...

The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Dennis Moynihan speaks about leadership in a way that anyone joining the webinar will gain insights that they can use immediately.

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

SNS Insider Reports Predict 3.59% CAGR from 2024-2032, with Clinical Chemistry and Stand-Alone Labs Leading the Growth SurgeAustin, April 16, 2025 (GLOBE NEWSWIRE) -- Clinical Laboratory Services ...